KalVista Pharmaceuticals (KALV) Tops Q3 EPS by 23c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q3 EPS of ($0.75), $0.23 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• GE Aerospace to acquire Consolidated Precision in $11.75b deal
• After an 18% summer selloff in chip stocks, Citi asks what comes next
• Citi turns more bullish on trucking stocks